Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Epstein-Barr virus (EBV) and its encoded oncoprotein, latent membrane protein 1 (LMP1), are closely associated with the transformation of nasopharyngeal carcinoma (NPC) and Burkitt's lymphoma (BL).
|
26244812 |
2015 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The LMP1 and EBNA2 genes were transiently expressed from heterologous promoters in two human T-cell lines (HPB-ALL and Jurkat), two human cell lines of the myeloid lineage (K562 and U937), one type I Burkitt's lymphoma cell line (Rael) and in human primary T cells and B-cell chronic lymphocytic leukemia cells.
|
8093369 |
1993 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LMP1 effects were also evaluated in the EBV-negative B-lymphoma cell line BL41 and the EBV-positive Burkitt's lymphoma cell line, Daudi (Daudi is deleted for EBNA-2 and does not express LMP).
|
2157887 |
1990 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we established an in vitro system representing the Burkitt's lymphoma (BL)-type Epstein-Barr virus (EBV) infection which is characterized by expression of EBV-determined nuclear antigen 1 (EBNA-1) and absence of EBNA-2 and latent membrane protein 1 (LMP1) expression.
|
9765461 |
1998 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we report that clones of the BL line Mutu that differ in expression of LMP 1 also show a differential methylation pattern of the LMP 1 regulatory sequences: this region is hypomethylated in an LMP 1 expressing (group III) clone but methylated in a group I clone that does not express LMP 1.
|
8178450 |
1994 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because the effects of LMP1 have been most closely studied in human Burkitt Lymphoma (BL) cell lines retaining a tumor biopsy-like phenotype in vitro, we have examined the response of a panel of such lines to CD40 ligation.
|
10092782 |
1999 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Considering that NF-κB, MYC and LMP-1 play a crucial role in the biology of many blood cancers including BL, our results provide a strong preclinical rationale for considering PL in new intervention approaches for patients with hematologic malignancies.
|
23237561 |
2013 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Northern blotting revealed high levels of miR-146a and miR-155 in the Burkitt's lymphoma cell line Jijoye which expresses LMP1 while the LMP1-deficient P3HR1 mutant derived from Jijoye expresses less miR-146a or miR-155.
|
18347435 |
2007 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that IL-10 was specifically induced by the EBV-latent membrane protein 1 (LMP1) in Burkitt's lymphoma (BL) cell lines BL2 and BL41.
|
11162833 |
2001 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-4 induced LMP-1 also in Burkitt lymphoma-derived lines and in tonsillar B cells infected with the EBNA-2-deficient EBV strain P3HR-1.
|
20876453 |
2011 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines.
|
8157362 |
1994 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alignment of this region for the 112 EBV genomes revealed four distinct patterns, tentatively termed patterns A to D. The distribution of BL EBVs was 48%, 8%, 24% and 20% for patterns A to D, respectively; the NPC EBV's were Pattern B, and EBV-WT was pattern D. Further work is needed to investigate the association between EBV LMP-1 patterns with BL.
|
26593963 |
2015 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD69 expression was upregulated in LMP-1‑expressing EBV-immortalized human B-cell lines and an EBV-positive Burkitt's lymphoma cell line.
|
23546309 |
2013 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we show that LMP1 negatively regulates a major oncogene, TCL1, in diffuse large B-cell lymphoma (DLBCL) and BL cells.
|
19966860 |
2010 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The latent membrane protein 1 (LMP1) is likely to play a determinant role in this process since this EBV encoded protein has oncogenic properties and is usually expressed in EBV-associated lymphoproliferative diseases (LPD), except Burkitt's lymphoma.
|
9160892 |
1997 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have shown that Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) is uniquely able to up-regulate the expression of the peptide transporters (referred to as TAP-1 and TAP-2) and major histocompatibility complex (MHC) class I in Burkitt's lymphoma (BL) cell lines.
|
11799186 |
2002 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies of EBV-converted and stably transfected BL cell lines demonstrated that the EBV gene LMP-1 is neither necessary nor sufficient to block the TGF-beta1 response.
|
10811940 |
2000 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The absence of del-LMP-1 within all EBV+ BL cases is consistent with the view that del-LMP-1 is not involved in the pathogenesis of BL, and the presence of del-LMP-1 in EBV+ cases of BL reported in other studies may likely reflect the prevalence of a viral strain containing the 30-bp deletion within the respective population studied.
|
9042791 |
1997 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Infection with Epstein-Barr virus (EBV) and its encoded latent membrane protein 1 (LMP1) play oncogenic roles in Burkitt's lymphoma (BL).
|
25591797 |
2015 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LMP promoter cat gene constructs were more active in a Burkitt's lymphoma cell line latently infected with the B95 EBV strain than in the same cells latently infected with the P3HR1 EBV strain.
|
2157069 |
1990 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Latency type III infection of Burkitt's lymphoma cell lines with immortalization-competent virus expressing the full set of latency genes selectively decreased the expression of SERCA3 protein, whereas infection with immortalization-deficient virus that does not express the EBNA2 or LMP-1 viral genes was without effect.
|
19650915 |
2009 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results suggest that expression of LMP1 at levels which are compatible with immortalization of normal B-cells antagonizes the ability of BL cells to grow in vitro and in vivo, and illustrate a possible mechanism by which down-regulation of this viral antigen may favor tumorigenicity in EBV-carrying BLs.
|
1322379 |
1992 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Histone deacetylase inhibitor-stimulated endogenous LMP-1 also induced CCL20 expression in an EBV-positive BL cell line.
|
16409294 |
2006 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Latency III (Lat III) in group III BL and EBV-transformed lymphoblastoid cell lines (LCLs) is characterized by expression of EBNAs 1, 2, 3a, 3b, 3c, and -LP from mRNAs driven by the Cp or Wp promoter and of the latent membrane proteins (LMPs 1, 2A, and 2B) from mRNAs driven by the LMP promoters.
|
1310556 |
1992 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, to identify targets of LMP1 that are regulated through PARP1, LMP1 was ectopically expressed in an EBV-negative Burkitt's lymphoma cell line.
|
30395643 |
2018 |